Endomag raises over £1700 for Cancer Research UK

Posted on by zymecom

As part of Cancer Research UK’s ‘Try It Triathlon’ challenge, Endomag collectively completed more than 31 triathlons in October

 Cambridge, UK, 1 November 2018: Endomag, the surgical guidance company, today announced it has raised over £1700 for Cancer Research UK by taking part in the Try It Triathlon challenge throughout October. A team of 15 staff members have managed to complete the distance of over 31 triathlons – the equivalent of one triathlon per day.

As a developer of surgical devices for use in cancer treatment, Endomag decided to raise money for Cancer Research UK through collectively swimming, cycling and running. The Company aimed to complete as many triathlons as possible in October and with an initial team of 10, the participants set out to swim, cycle, and run the equivalent of 10 Olympic triathlons. With more people volunteering throughout the month, it became apparent that Endomag could achieve more, and the team even carried on with the challenge during visits to hospitals and businesses in Australia and Germany.

An Olympic triathlon comprises 1.5km swimming, 40km cycling, and 10km running. Endomag completed 47.9km swimming, 1453.8km cycling and 323.7km running, more than three times their original goal. Money has been raised through donations to the online fundraising page and as of November 1st has reached £859. The donations page will remain open until 9th November, and the final sum will be matched by Endomag, bringing the total to £1718 so far.

To make a donation, please visit https://fundraise.cancerresearchuk.org/page/endomag-try-it-triathlon

Dr Eric Mayes, CEO at Endomag said: “We’re so pleased with what the team here at Endomag has been able to achieve. Cancer Research UK is a fantastic charity that we feel passionately about supporting. Knowing the impact that our fundraising will have on life-saving cancer research has been a huge motivation throughout the Try It Triathlon challenge.”

 Cancer Research UK hope to accelerate progress in cancer prevention, diagnosis and treatment and see three-quarters of people surviving the disease within the next 20 years.

 To learn more about Endomag, visit: www.endomag.com

This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.